These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 21717904)

  • 1. Evolving therapeutic paradigms for advanced prostate cancer.
    Ruch JM; Hussain MH
    Oncology (Williston Park); 2011 May; 25(6):496-504, 508. PubMed ID: 21717904
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current and emerging treatments in the management of castration-resistant prostate cancer.
    Shapiro D; Tareen B
    Expert Rev Anticancer Ther; 2012 Jul; 12(7):951-64. PubMed ID: 22845410
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Angiogenesis and anti-angiogenic therapy in prostate cancer.
    Mukherji D; Temraz S; Wehbe D; Shamseddine A
    Crit Rev Oncol Hematol; 2013 Aug; 87(2):122-31. PubMed ID: 23375349
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New therapies for castration-resistant prostate cancer: efficacy and safety.
    Beltran H; Beer TM; Carducci MA; de Bono J; Gleave M; Hussain M; Kelly WK; Saad F; Sternberg C; Tagawa ST; Tannock IF
    Eur Urol; 2011 Aug; 60(2):279-90. PubMed ID: 21592649
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New and emerging agents for the treatment of castration-resistant prostate cancer.
    Higano CS; Crawford ED
    Urol Oncol; 2011; 29(6 Suppl):S1-8. PubMed ID: 22074657
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Abiraterone acetate in castration-resistant prostate cancer.
    Iacovelli R; Palazzo A; Procopio G; Gazzaniga P; Cortesi E
    Anticancer Drugs; 2012 Mar; 23(3):247-54. PubMed ID: 22123334
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent advances in second-line treatment of castration-resistant prostate cancer.
    Ong M; Winquist E
    Curr Opin Support Palliat Care; 2011 Sep; 5(3):199-205. PubMed ID: 21734586
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New developments in castrate-resistant prostate cancer.
    Shore N; Mason M; de Reijke TM
    BJU Int; 2012 Jun; 109 Suppl 6():22-32. PubMed ID: 22672122
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel strategies in the treatment of castration-resistant prostate cancer (Review).
    Marech I; Vacca A; Ranieri G; Gnoni A; Dammacco F
    Int J Oncol; 2012 May; 40(5):1313-20. PubMed ID: 22322981
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New drugs in prostate cancer.
    Armstrong AJ; Carducci MA
    Curr Opin Urol; 2006 May; 16(3):138-45. PubMed ID: 16679849
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel chemotherapies in development for management of castration-resistant prostate cancer.
    Tewari AK; George DJ
    Curr Opin Urol; 2013 May; 23(3):220-9. PubMed ID: 23511791
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular alterations and emerging targets in castration resistant prostate cancer.
    Lorente D; De Bono JS
    Eur J Cancer; 2014 Mar; 50(4):753-64. PubMed ID: 24418724
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Castration-resistant prostate cancer: many treatments, many options, many challenges ahead.
    Garcia JA; Rini BI
    Cancer; 2012 May; 118(10):2583-93. PubMed ID: 22038761
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
    Kijima T; Fujii Y; Yokoyama M; Ishioka J; Matsuoka Y; Numao N; Saito K; Koga F; Masuda H; Kawakami S; Kihara K
    BJU Int; 2012 Oct; 110(8):1149-55. PubMed ID: 22369348
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel agents for the management of castration-resistant prostate cancer.
    Haddad H; Garcia JA
    Curr Opin Urol; 2012 May; 22(3):175-82. PubMed ID: 22472509
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Castration-refractory prostate cancer: New drugs in the pipeline.
    Schrijvers D; Van Erps P; Cortvriend J
    Adv Ther; 2010 May; 27(5):285-96. PubMed ID: 20532721
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical roundtable monograph: new and emerging treatments for advanced prostate cancer.
    George DJ; Kantoff PW; Lin DW
    Clin Adv Hematol Oncol; 2011 Jun; 9(6):1-11; discussion 11-5. PubMed ID: 21941983
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel therapeutics for the management of castration-resistant prostate cancer (CRPC).
    Lee DJ; Cha EK; Dubin JM; Beltran H; Chromecki TF; Fajkovic H; Scherr DS; Tagawa ST; Shariat SF
    BJU Int; 2012 Apr; 109(7):968-85. PubMed ID: 22035221
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emerging therapies in metastatic castration-sensitive and castration-resistant prostate cancer.
    MacVicar GR; Hussain MH
    Curr Opin Oncol; 2013 May; 25(3):252-60. PubMed ID: 23511665
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emerging and second line therapies for the management of metastatic castration-resistant prostate cancer: the Australian perspective.
    Parente P; Parnis F; Gurney H
    Asia Pac J Clin Oncol; 2012 Mar; 8(1):31-42. PubMed ID: 22369442
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.